Blister Packages | © PhotoAlto/Sigrid Olsson/Getty Images
Perfect combination of tradition, innovation, and attractive costs
Germany is the best international location for the research, production, and distribution of pharmaceuticals at an exceptionally high level. Direct access to internationally renowned scientists, outstanding research units, and major pharmaceutical markets make Germany a unique business location. The development of the world’s population structure is creating new challenges and is leading to increased demand for pharmaceuticals. This, together with significant advancements in medical biotechnology research, is giving the pharmaceutical industry new impetus worldwide.
- The German pharmaceutical market is the largest in Europe and the fourth largest in the world. The annual sales of medicinal products total more than EUR 41.5 (2017) and this figure continues to experience sustained growth (+5% in 2017 vs. previous year).
- 1170 pharmaceutical and biotechnology companies with more than 128,000 workers (2015) operate in Germany. In addition to globally successful enterprises, the industry composed of more than 800 medium-sized businesses and young biotech companies.
- German companies invest EUR 6.2 billion (2016) annually in research and development.
- Top 10 of the most important indications on the statutory health insurance market in terms of sales (2016):
|Top 10 of the most important indications (ATC-3) on the statutory health insurance market in terms of sales (2016)|
|Indication areas (ATC-3)|
|% vs. previous year||% share of total sales||% share of total quantity|
|L04B Anti-TNF products|
|N07A Multiple sclerosis Product||1,730.90||- 0.91||4.48||0.08|
|A10C Human insulin and analogues|
|L01H Antineoplastic protein kinase inhibitors||1,385.20||15.61||3.58||0.04|
|B01F Direct factor-Xa inhibitors||1,070.90||32.09||2.77||0.65|
|N02A Analgesics, Anaesthetic agents||1.061,70||3.18||2.75||1.18|
|J05B Virostatic agents, not for HIV||961.80||- 35.71||2.49||0.16|
|J05C Virostatic agents for HIV||961.50||3.68||2.49||0.09|
|L04X Other immunosuppressants|
|T02D Diabetes tests|
Source: BPI 2017
Within Europe, Germany is the leading market for non-prescription medicines, so-called OTC (over-the-counter) products. OTC refers to medicinal products which may be sold only in pharmacies but for which no prescription is required.
The annual sales of non-prescription medicinal products total more than EUR 8.7 billion (2017, with growth of +3.7% vs. previous year). The largest share of self-medication products is accounted for by pharmacies with 69% (EUR 7.2 billion), followed by drug stores, supermarkets, and mail-order pharmacies. The three best-selling product groups include cold remedies, analgesics, and skin products.
Over the Counter (OTC) Medicine | © IMS Health 2018
The pharmaceutical industry in Germany manufactures pharmaceutical products worth over EUR 29 billion annually (2016).
In addition to its central location in the heart of Europe, Germany offers an excellent, well-developed, nationwide infrastructure. The most modern transportation networks work in coordination with a high-quality communication and energy infrastructure. Hundreds of thousands of highly qualified workers from the areas of medical technology, pharmaceutical technology, and mechanical engineering enable companies to implement efficient and complex production processes. Pharmaceutical companies in Germany also benefit from the close proximity to leading machine and plant manufacturers. This ensures continuous production processes and reduces downtime. Germany accounts for approximately 37 % of the total production of machinery and plants in Europe.
Germany has become one of the world’s most important countries for clinical studies. Germany is the leader in industry-initiated clinical studies in Europe and second worldwide. The dense network of universities and faculties as well as a variety of research institutions not affiliated to universities speak in favor of Germany as a business location.
Dr. Hagen Pfundner, CEO Roche Pharma AG and Managing Director Roche Deutschland Holding GmbH
Dr. Hagen Pfundner, CEO Roche Pharma AG and Managing Director Roche Deutschland Holding GmbH | © Roche Deutschland Holding GmbH
"The availability of a highly trained labor force, a secure legal framework, the company’s own long tradition in Germany, and a proven record in biopharmaceutical production were determining factors for the site expansion."
The pharmaceutical industry is represented by several associations:
German Association of Research-based Pharmaceutical Companies (vfa): The vfa represents the interests of 44 global leaders in research-based pharmaceutical companies and more than 100 subsidiaries and affiliated companies in healthcare, research, and economic policy.
German Association for the Pharmaceutical Industry (BPI): The BPI represents approx. 240 companies. This includes traditional pharmaceutical companies, pharmaceutical service providers, and companies in the fields of biotechnology, herbal medicine and homeopathy/anthroposophy.
German Association of Pharmaceutical Producers (BAH): With more than 450 members, the BAH has the most members among the pharmaceutical industry associations in Germany. Its members are primarily pharmaceutical producers, but also pharmacists, lawyers, publishers, agencies, as well as market and opinion research institutes in the healthcare field.
Pro Generika: Pro Generika is the association of companies that manufacture generic and biosimilar products in Germany. Pro Generika has 16 member companies in Germany. Companies manufacturing generic and biosimilar products together cover over 75 percent of the medicinal drugs required by the statutory health insurance funds.